Patents by Inventor Weiguang Mao

Weiguang Mao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-LGR5 ANTIBODIES AND USES THEREOF
    Publication number: 20190248889
    Abstract: The invention provides anti-LgR5 antibodies and methods of using the same.
    Type: Application
    Filed: April 22, 2019
    Publication date: August 15, 2019
    Applicant: GENENTECH, INC.
    Inventors: Andrew G. Polson, Weiguang Mao, Ron Firestein
  • Anti-LGR5 antibodies and uses thereof
    Patent number: 10316084
    Abstract: The invention provides anti-LgR5 antibodies and methods of using the same.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: June 11, 2019
    Assignee: GENENTECH, INC.
    Inventors: Andrew G. Polson, Weiguang Mao, Ron Firestein
  • ANTI-LGR5 ANTIBODIES AND USES THEREOF
    Publication number: 20170233471
    Abstract: The invention provides anti-LgR5 antibodies and methods of using the same.
    Type: Application
    Filed: November 29, 2016
    Publication date: August 17, 2017
    Applicant: GENENTECH, INC.
    Inventors: Andrew G. Polson, Weiguang Mao, Ron Firestein
  • CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20170166635
    Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p ??(I) where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 15, 2017
    Inventors: Weiguang Mao, Jagath Reddy Junutula, Paul Polakis
  • ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20160102146
    Abstract: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: September 17, 2015
    Publication date: April 14, 2016
    Applicant: GENENTECH, INC.
    Inventors: Jo-Anne Hongo, Weiguang Mao, Paul Polakis, Andrew Polson, Rajesh Vij, Yan Wu, Wei-Ching Liang
  • Anti-LGR5 antibodies and immunoconjugates
    Patent number: 9175089
    Abstract: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: November 3, 2015
    Assignee: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Weiguang Mao, Paul Polakis, Andrew Polson, Rajesh Vij, Yan Wu, Wei-Ching Liang
  • CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20150158952
    Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: November 24, 2014
    Publication date: June 11, 2015
    Applicant: GENENTECH, INC.
    Inventors: Weiguang MAO, Jagath Reddy JUNUTULA, Paul POLAKIS
  • Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
    Patent number: 8937161
    Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: January 20, 2015
    Assignee: Genentech, Inc.
    Inventors: Weiguang Mao, Jagath Reddy Junutula, Paul Polakis
  • ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20130336885
    Abstract: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: March 29, 2013
    Publication date: December 19, 2013
    Applicant: GENENTECH INC.
    Inventors: Jo-Anne Hongo, Weiguang Mao, Paul Polakis, Andrew Polson, Rajesh Vij, Yan Wu, Wei-Ching Liang
  • Humanized anti-TGF-beta antibodies
    Patent number: 8012482
    Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: September 6, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Napoleone Ferrara, Ellen Filvaroff, Weiguang Mao, Leonard G. Presta, Max L. Tejada
  • ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME
    Publication number: 20100278842
    Abstract: The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates.
    Type: Application
    Filed: June 8, 2010
    Publication date: November 4, 2010
    Applicant: Genentech, Inc.
    Inventors: Weiguang Mao, Paul Polakis
  • Anti-EphB2 antibodies and methods using same
    Patent number: 7767205
    Abstract: The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: August 3, 2010
    Assignee: Genentech, Inc.
    Inventors: Weiguang Mao, Paul Polakis
  • HUMANIZED ANTI-TGF-BETA ANTIBODIES
    Publication number: 20090285810
    Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
    Type: Application
    Filed: April 14, 2009
    Publication date: November 19, 2009
    Applicant: GENENTECH, INC.
    Inventors: Camellia W. Adams, Napoleone Ferrara, Ellen H. Filvaroff, Weiguang Mao, Leonard G. Presta, Max L. Tejada
  • Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
    Publication number: 20090117100
    Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: October 16, 2008
    Publication date: May 7, 2009
    Inventors: Weiguang Mao, Jagath Reddy Junutula, Paul Polakis
  • Humanized anti-TGF-beta antibodies
    Patent number: 7527791
    Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: May 5, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Napoleone Ferrara, Ellen H. Filvaroff, Weiguang Mao, Leonard G. Presta, Max L. Tejada
  • ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME
    Publication number: 20080254024
    Abstract: The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates.
    Type: Application
    Filed: July 31, 2007
    Publication date: October 16, 2008
    Applicant: Genentech, Inc.
    Inventors: Weiguang Mao, Paul Polakis
  • Humanized anti-TGF-beta antibodies
    Publication number: 20050276802
    Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
    Type: Application
    Filed: March 31, 2005
    Publication date: December 15, 2005
    Applicant: Genentech, Inc.
    Inventors: Camellia Adams, Napoleone Ferrara, Ellen Filvaroff, Weiguang Mao, Leonard Presta, Max Tejada